Orbit (Amsterdam, Netherlands) · 2025
A new, porous, ultra-high molecular weight, polyethylene orbital implant with innovative suturing platform (EZYPOR): a retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Javate Reynaldo M, Sioson Jacquelyn Yvette G
Аннотация
PURPOSE: This study reports on patient outcomes associated with the placement of a new, porous, ultra-high molecular weight polyethylene (UHMWPE) orbital implant with an innovative suturing platform (EZYPOR (PP)) after primary or secondary enucleation.
METHODS: This was a descriptive, retrospective study of patients who underwent EZYPOR (PP) orbital implantation after primary or secondary enucleation for over a 36-month period done at the University of Santo Tomas Hospital (USTH), Manila, Philippines. The data collected included demographics, surgical indications, implant-associated postoperative outcomes, and follow-up duration.
RESULTS: A total of 21 patients were eligible for this study. The most common surgical indications for enucleation were phthisis bulbi (33%), absolute glaucoma (23.81%) and endophthalmitis (14.29%). No postoperative complications, such as conjunctival thinning, implant exposure, enophthalmos, ptosis, or eyelid malposition, were noted throughout the follow-up period (MD = 811 days).
CONCLUSION: The EZYPOR (PP) orbital implant is a new and reliable porous orbital implant with advantages over existing porous orbital implants that are widely used today. It is designed and manufactured to increase tolerability, is easy to implant, and has good patient outcomes, such as satisfactory socket motility, good cosmetic appearance, and no postoperative complications related to the EZYPOR (PP) orbital implant in the 36 months follow-up, albeit with a limited number of patients. This study offers important baseline information for ophthalmologists' evidence-based guidance in the adoption of new porous orbital implants with an innovative suturing platform. Finally, the EZYPOR (PP) orbital implant is 30% less expensive than other major commercially available porous orbital implants.
METHODS: This was a descriptive, retrospective study of patients who underwent EZYPOR (PP) orbital implantation after primary or secondary enucleation for over a 36-month period done at the University of Santo Tomas Hospital (USTH), Manila, Philippines. The data collected included demographics, surgical indications, implant-associated postoperative outcomes, and follow-up duration.
RESULTS: A total of 21 patients were eligible for this study. The most common surgical indications for enucleation were phthisis bulbi (33%), absolute glaucoma (23.81%) and endophthalmitis (14.29%). No postoperative complications, such as conjunctival thinning, implant exposure, enophthalmos, ptosis, or eyelid malposition, were noted throughout the follow-up period (MD = 811 days).
CONCLUSION: The EZYPOR (PP) orbital implant is a new and reliable porous orbital implant with advantages over existing porous orbital implants that are widely used today. It is designed and manufactured to increase tolerability, is easy to implant, and has good patient outcomes, such as satisfactory socket motility, good cosmetic appearance, and no postoperative complications related to the EZYPOR (PP) orbital implant in the 36 months follow-up, albeit with a limited number of patients. This study offers important baseline information for ophthalmologists' evidence-based guidance in the adoption of new porous orbital implants with an innovative suturing platform. Finally, the EZYPOR (PP) orbital implant is 30% less expensive than other major commercially available porous orbital implants.